DAIC

MAY 6, 2024

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

American College of Cardiology

DECEMBER 14, 2023

Bailey MD, FACC, discuss the Top Takeaways from 2023 in Heart Failure. In this interview, Clyde Yancy MD, MSc, FACC, and Alison L.

Heart Failure 57

Heart Failure Article 57

The British Journal of Cardiology

FEBRUARY 20, 2024

Multidisciplinary experts in heart failure care from across the UK and wider afield gathered for the recent 26th British Society of Heart Failure (BSH) annual meeting. Dr Aaron Henry reports highlights from the meeting.

Heart Failure 69

Heart Failure Technology Arrhythmia Obesity 69

DAIC

DECEMBER 19, 2023

Getty Images milla1cf Tue, 12/19/2023 - 18:09 December 19, 2023 — BioCardia, Inc. , Getty Images milla1cf Tue, 12/19/2023 - 18:09 December 19, 2023 — BioCardia, Inc. , This study follows BioCardia’s three previous co-sponsored clinical trials with MSCs in ischemic heart failure: TACHFT 1 , POSEIDON 2 and TRIDENT 3.

Heart Failure 105

Heart Failure Interventional Cardiology Pulmonary Heart Disease 105

Frontiers in Cardiovascular Medicine

JANUARY 31, 2025

IntroductionVentricular assist devices (VADs) are lifesavers for people with advanced heart failure. The design of these devices has undergone drastic changes over time with the latest designs being far more efficient, small, lightweight, and more user-friendly.

Document 80

Document Innovation Heart Failure Technology 80

Clinical Trial Results

DECEMBER 21, 2023

Disclosures: TBD

Heart Failure 76

Heart Failure 76

Cardiovascular Diabetology

AUGUST 11, 2024

We evaluated the prevalence of “heart stress” (HS) based on NT-proBNP cut-points proposed by the 2023 Consensus of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in asymptomati.

Blood Pressure 111

Blood Pressure Heart Failure Hypertension Diabetes 111

The British Journal of Cardiology

JUNE 11, 2024

In this article we focus on areas of the European Society for Cardiology (ESC) heart failure guideline 2023 update that will be most relevant in the day-to-day management of patients with heart failure.

Heart Failure 40

Heart Failure Article Outcomes 40

American College of Cardiology

FEBRUARY 5, 2024

Hypertension represents a major modifiable risk factor for coronary artery disease (CAD), heart failure (HF), stroke, chronic kidney disease (CKD), and dementia.

Hypertension 75

Hypertension Coronary Artery Disease Kidney Disease Dementia 75

Frontiers in Cardiovascular Medicine

MARCH 30, 2025

Infection (75.47%, 160/212) and heart failure (51.42%, 109/212) were common comorbidities. Demographic, clinical, and diagnostic data, as well as follow-up outcomes, were reviewed. In-hospital mortality was 5.19% (11/212), with follow-up mortality of 20.28% (43/212).

Risk Factors 52

Risk Factors Pediatrics Cardiomyopathy Pulmonary 52

European Journal of Heart Failure

FEBRUARY 5, 2025

Methods and results TRED-HF was a randomized trial investigating heart failure therapy withdrawal in patients with recovered DCM over 6months. Participants were recommended to restart therapy post-trial and were followed until May 2023. Those randomized to continue therapy subsequently withdrew treatment between 6 and 12months.

Heart Failure 67

Heart Failure Cardiomyopathy Atrial Fibrillation Arrhythmia 67

Frontiers in Cardiovascular Medicine

FEBRUARY 13, 2024

Heart failure (HF) is recognized as an epidemic in the contemporary world, impacting around 1%–2% of the adult population and affecting around 6 million Americans. billion in 2023, warranting a better understanding of the mechanisms involved in HF. HF remains a major cause of mortality, morbidity, and poor quality of life.

Heart Failure 64

Heart Failure Electrophysiology Quality of Life Arrhythmia 64

Medical Xpress - Cardiology

NOVEMBER 26, 2024

From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular ejection fraction (LVEF) greater than 40 percent, according to a study published online Nov. 16 to 18 in Chicago.

Heart Failure 52

Heart Failure 52

Cardiology Update

NOVEMBER 17, 2023

The Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference took place at the Moscone Center in San Francisco, USA from October 23 – 26, 2023. Dr. Chadi Alraies provides an overview of the top highlights from TCT 2023. The post TCT 2023 Highlights appeared first on Cardiology Update.

Research 52

Research Heart Failure Interventional Cardiology General Cardiology 52

European Journal of Heart Failure

JANUARY 3, 2024

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Co-ordinator) (Netherlands), P. Christian Schulze (CPG Review Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek (Belgium), Johann Bauersachs (Germany), Michael A.

Heart Failure 65

Heart Failure Document 65

Frontiers in Cardiovascular Medicine

FEBRUARY 20, 2024

Background Exercise training is commonly employed as a efficacious supplementary treatment for individuals suffering from heart failure, but the optimal exercise regimen is still controversial. 41.70), and Minnesota Living with Heart Failure Questionnaire (MD = −4.45, 95% CI for −6.25 to −2.64) compared to MICT.

Heart Failure 64

Heart Failure Exercise Quality of Life Cardiac Function 64

European Journal of Heart Failure

OCTOBER 31, 2023

This 2023 Cochrane review of 60 randomized trials in 8728 heart failure patients, confirms the benefits of participation in exercise-based cardiac rehabilitation (ExCR), including reduced risk of hospitalization and a clinically meaningful improvement in health-related quality of life.

Cardiac Rehabilitation 40

Cardiac Rehabilitation Heart Failure Exercise Quality of Life 40

CardiacWire

NOVEMBER 15, 2023

The AHA 2023 Scientific Sessions are officially complete. Prevention & Detection – Boosted by GLP-1 obesity buzz and the fact that cardiovascular outcome trends have been headed in the wrong direction, AHA 2023 placed a greater focus on prevention. heart failure).

Blood Pressure 52

Blood Pressure AFIB Obesity Heart Failure 52

Cardiometabolic Health Congress

NOVEMBER 16, 2023

2-5, 2023, to gain perspective on the latest advances in the management of glomerular disease. Kidney Week 2023 not only served as a platform for the latest news and updates in the field but also marked the final meeting of the year for practitioners in the specialty of nephrology.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

Cardiology Update

JANUARY 2, 2024

Important Deadlines: Early registration fee: January 9, 2023. Late registration fee: February 8, 2023. Important Deadlines: Abstract and late-breaking clinical trial submission is closed (Deadline: December 7 and October 17, 2023) Fees: Visit the ACC 2024 website for registration options. Hashtag: #ACVC2024 2. Hashtag: #ACC24 3.

Heart Failure 111

Heart Failure Atherosclerosis Cardiovascular Imaging Non-Invasive Cardiology 111

DAIC

MAY 18, 2024

Researchers presented these findings “Late Breaking Clinical Trials and Science – CIEDs: Early Cardiac Resynchronization Therapy for Patients with Moderately Reduced Ejection Fraction and Left Bundle Branch Block” this morning during the May 16-19 meeting of the Heart Rhythm Society , HRS 2024 , being held in Boston, MA. 2023 Oct;29(10):1412.

Heart Failure 52

Heart Failure Heart Rhythm Research Pacemaker 52

Journal of Cardiovascular Pharmacology

DECEMBER 20, 2023

Background: Midodrine is occasionally used off-label to treat hypotension associated with advanced heart failure. Objectives: We sought to evaluate the effect of midodrine upon the GDMT prescription pattern and clinical outcomes of patients with decompensated systolic heart failure. All rights reserved.

Heart Failure 52

Heart Failure Hospital Outcomes Article 52

Frontiers in Cardiovascular Medicine

FEBRUARY 28, 2024

Objective To compare the efficacy of LBBP and BiVP in patients with heart failure (HF) complicated with CLBBB. Secondary endpoints were all-cause mortality, heart failure hospitalization (HFH), NT-proBNP, paced QRS duration, pacing threshold, and procedural duration. Methods This was a single-center retrospective study.

Heart Failure 64

Heart Failure Physiology Cardiomyopathy Hospital 64

All About Cardiovascular System and Disorders

OCTOBER 16, 2023

Current Role of Digoxin in Heart Failure as Per Guidelines and DIGIT-HF trial of Digitoxin Use of digoxin in heart failure has come down markedly over the past decades due to concerns of toxicity and availability of more effective medications. Eur Heart J. Erratum in: Eur Heart J. Eur J Heart Fail.

Heart Failure 52

Heart Failure Atrial Fibrillation Document Hospital 52

Frontiers in Cardiovascular Medicine

DECEMBER 17, 2023

Objectives Our study was to evaluate the effect of Qishen Yiqi Dropping Pills(QSYQ) on the prognosis of chronic ischemic heart failure(CIHF) and its safety. Primary indicators included readmission rates, rates of major adverse cardiovascular events (MACE), and all-cause mortality rates.

Heart Failure 64

Heart Failure Quality of Life Cardiac Function Exercise 64

HeartRhythm

SEPTEMBER 25, 2024

Atrial fibrillation (AF) is a common reversible cause of worsening left ventricular ejection fraction (LVEF) in patients with heart failure. Guidelines propose a class 1 recommendation for AF catheter ablation (CA) in patients with heart failure with reduced ejection fraction1,2.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation 40

European Journal of Heart Failure

DECEMBER 11, 2024

Abstract Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock.

Cardiogenic Shock 68

Cardiogenic Shock Heart Disease Heart Failure Bicuspid/Mitral 68

Frontiers in Cardiovascular Medicine

JANUARY 24, 2024

Background There is controversy in relation to commonly used drugs in heart failure (HF) and their impact on muscle function. Methods A systematic literature search of cohort studies via databases (PubMed, Web of Science, Scopus, and Cochrane Library) was conducted from inception until March 2023.

Heart Failure 64

Heart Failure 64

European Journal of Heart Failure

NOVEMBER 19, 2024

Knowledge and application of European Society of Cardiology/Heart Failure Association (ESC/HFA) guidelines in the management of advanced heart failure (HF). Methods and results From June to October 2023, an online survey was disseminated through the ESC mailing list, targeting cardiologists across Europe.

Heart Failure 40

Heart Failure Transplant Heart Transplant Education 40

Open Heart

DECEMBER 14, 2023

Objectives (1) Develop a programme theory of why, for whom and in what contexts integrated palliative care (PC) and heart failure (HF) services work/do not work; (2) use the programme theory to co-produce with stakeholders, intervention strategies to inform best practice and future research.

Heart Failure 52

Heart Failure Document Best Practices Education 52

DAIC

FEBRUARY 12, 2024

A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health. and Allina Health. and Allina Health.

Heart Failure 52

Heart Failure Hospital Quality of Life Heart Attack 52

Journal of Cardiovascular Electrophysiology

APRIL 10, 2025

ABSTRACT Background Despite leadless pacemakers (LPMs) showing promise, real-world data comparing them to transvenous pacemakers (TV-VVI) are insufficient and often contradictory, especially in patients without major comorbidities like heart failure. Objectives Comparing LPMs with TV-VVIs in real-world patients without HF.

Pacemaker 40

Pacemaker Heart Failure Atrial Fibrillation Bradycardia 40

DAIC

JANUARY 23, 2024

Getty Images milla1cf Tue, 01/23/2024 - 13:38 January 23, 2024 — Sequana Medical NV , a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announced that an independent Data and Safety Monitoring Board (DSMB) approved the start of the randomized cohort in MOJAVE , the US Phase 1/2a study of DSR 2.0

Heart Failure 104

Heart Failure Preserved Ejection Fraction Hypertension Cancer 104

European Journal of Heart Failure

DECEMBER 18, 2024

KCCQ-12, 12-question Kansas City Cardiomyopathy Questionnaire; NT-proBNP, N-terminal pro-B-type natriuretic peptide Abstract Aims We sought to characterize the clinical course of patients following worsening heart failure (WHF) treated in an outpatient setting and to identify factors associated with a poor response to standard of care with loop diuretics. (..)

Outpatient 40

Outpatient Heart Failure Cardiomyopathy Research 40

DAIC

JULY 3, 2024

Jon Kobashigawa, MD, of the Smidt Heart Institute at Cedars-Sinai, is an expert in heart transplantation, heart failure, and other complex cardiac conditions. An expert in diagnosing heart failure, Kobashigawa also is director of the Advanced Heart Disease Division in the Smidt Heart Institute.

Transplant 105

Transplant Heart Transplant Heart Failure Education 105

Circulation: Heart Failure

SEPTEMBER 27, 2023

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010849, November 1, 2023. 1.94]), incident heart failure with reduced ejection fraction (1.48 [95% CI, 1.08–2.02]), 1.77]) but not incident coronary heart disease (0.97 [95% CI, 0.71–1.34]). 2.02]), and incident AF (1.44 [95% CI, 1.18–1.77])

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Heart Disease 40

Circulation: Cardiovascular Imaging

APRIL 3, 2025

BACKGROUND:Microvascular obstruction (MVO) is associated with heart failure (HF) following ST-segmentelevation myocardial infarction. Circulation: Cardiovascular Imaging, Ahead of Print. AMR was computed from coronary angiography. MVO was identified and quantified via cardiac magnetic resonance. years; 399 males) were included.

Heart Failure 40

Heart Failure Myocardial Infarction STEMI Risk Factors 40